Johnson & Johnson's OTTAVA Robotic System Clears Key Clinical Hurdle

Event summary

  • OTTAVA™ Robotic Surgical System met primary safety and performance endpoints in a 30-patient clinical study for Roux-en-Y gastric bypass procedures.
  • Average weight loss of 30 pounds observed 30 days post-surgery, with all procedures completed robotically without conversion.
  • System's novel architecture integrates four robotic arms into a standard surgical table, enabling use in ORs as small as 243 sq. ft.
  • Data submitted to FDA for De Novo classification targeting multiple general surgery procedures.

The big picture

Johnson & Johnson's OTTAVA™ system represents a strategic push into next-generation surgical robotics, targeting the growing demand for minimally invasive bariatric procedures. With over 40% of U.S. adults affected by obesity, the system's potential to expand robotic surgery access could reshape the $2.5B global surgical robotics market. The novel architecture addresses key adoption barriers, positioning OTTAVA™ as a potential disruptor in a space currently dominated by Intuitive Surgical's da Vinci systems.

What we're watching

Regulatory Approval
Whether the FDA will grant De Novo classification for OTTAVA™, enabling broader market access.
Clinical Adoption
The pace at which hospitals integrate OTTAVA™ into existing OR workflows, particularly in space-constrained environments.
Market Differentiation
How OTTAVA™'s novel architecture positions it against established robotic surgical systems in the bariatric surgery space.